Clinical trial · Observational
Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer
A Single-center，Observational，Ambispective Cohort Study of Regorafenib Versus Fruquintinib in Metastatic Colorectal Cancer Patients Who Have Progressed After at Least Second Lines of Chemotherapies
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an observational, ambispective cohort study. The aim is to compare the efficacy and safety of regorafenib versus fruquintinib conducted in China. About 268 eligible metastatic colorectal cancer patients after second-line therapy will be assigned to receive either regorafenib or fruquintinib, based on decision of the gastrointestinal physician according the patients' condition.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fruquintinib | Drug | Fruquintinib | ALIAS |
| Regorafenib | Drug | Regorafenib | ALIAS |
Design
Arms and outcomes
Arms (2)
- label
- Regorafenib
- interventionNames
- Drug: Regorafenib
- label
- Fruquintinib
- interventionNames
- Drug: Fruquintinib
Primary outcomes (1)
- measure
- Time To Treatment Failure
- timeFrame
- every month, up to discontinuation of treatment for any reason.
- description
- the time from first dose to discontinuation of treatment for any reason, including disease progression, treatment toxicity, and death.
Secondary outcomes (3)
- measure
- Overall survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. signed and dated informed consent. 2. Diagnosis of histologically confirmed colorectal cancer, stage IV. 3. after second-line therapy. 4. gastrointestinal physician prescribed to receive regorafenib or fruquintinib according the patients' condition. Exclusion Criteria: 1. received regorafenib or fruquintinib before third-line therapy. 2. the clinicopathological characteristics and previous therapy were unknown. 3. regorafenib or fruquintinib treatment is less than one cycle in the historical cohort.
References
Publications (0)
Data not yet available